Bristol Myers Squibb (NYSE: BMY) announced it will enroll additional patients in its ADEPT-2 Phase 3 study evaluating Cobenfy for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE